Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Price Expected to Rise, Truist Financial Analyst Says

Key Points

• Truist Financial raised its Jazz Pharmaceuticals price target to $281 from $264 and maintained a “Buy” rating, implying 8.78% upside from the $258.32 share price. Other analysts remain broadly positive, with the stock carrying an overall “Buy” rating and an average target of $275.95.
• Jazz reported quarterly revenue of $1.21 billion, up 15.5% year over year and above estimates, but adjusted EPS of $5.71 missed consensus by $0.47. Analysts expect the company to earn $21.66 per share for the current fiscal year.
• Institutional investors own 89.14% of Jazz, while insiders have sold shares worth about $3.5 million over the past 90 days. The company is also pursuing a $1 billion exchangeable senior-notes offering alongside share repurchases, which could support per-share value but adds financing obligations and potential dilution.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) had its price target raised by investment analysts at Truist Financial from $264.00 to $281.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The firm presently has a "buy" rating on the specialty pharmaceutical company's stock. Truist Financial's price target would suggest a potential upside of 8.78% from the company's current price.

A number of other equities research analysts also recently weighed in on JAZZ. Needham & Company LLC lifted their target price on Jazz Pharmaceuticals from $292.00 to $310.00 and gave the stock a "buy" rating in a research report on Wednesday. Barclays upped their target price on Jazz Pharmaceuticals from $260.00 to $270.00 and gave the company an "overweight" rating in a research note on Tuesday, August 4th. Stifel Nicolaus set a $275.00 price objective on shares of Jazz Pharmaceuticals in a research note on Tuesday, August 4th. Raymond James Financial reiterated an "outperform" rating and set a $239.00 target price on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 6th. Finally, Weiss Ratings upgraded shares of Jazz Pharmaceuticals from a "hold (c-)" rating to a "buy (b-)" rating in a research note on Tuesday, August 4th. One analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat.com, Jazz Pharmaceuticals presently has an average rating of "Buy" and an average target price of $275.95.

Jazz Pharmaceuticals Stock Performance

Shares of NASDAQ:JAZZ traded down $1.91 during trading on Wednesday, reaching $258.32. The stock had a trading volume of 508,070 shares, compared to its average volume of 929,000. The stock has a fifty day simple moving average of $245.93 and a two-hundred day simple moving average of $216.92. The company has a quick ratio of 1.58, a current ratio of 1.78 and a debt-to-equity ratio of 0.69. Jazz Pharmaceuticals has a 52 week low of $123.87 and a 52 week high of $266.38. The firm has a market capitalization of $16.77 billion, a price-to-earnings ratio of 17.79, a P/E/G ratio of 0.23 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its quarterly earnings results on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $6.18 by ($0.47). Jazz Pharmaceuticals had a net margin of 20.45% and a return on equity of 33.97%. The firm had revenue of $1.21 billion for the quarter, compared to the consensus estimate of $1.11 billion. During the same quarter last year, the company earned ($8.25) earnings per share. The firm's revenue was up 15.5% on a year-over-year basis. As a group, analysts anticipate that Jazz Pharmaceuticals will post 21.66 earnings per share for the current fiscal year.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Bruce C. Cozadd sold 6,000 shares of Jazz Pharmaceuticals stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $252.98, for a total transaction of $1,517,880.00. Following the completion of the sale, the director owned 360,682 shares of the company's stock, valued at approximately $91,245,332.36. The trade was a 1.64% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Neena M. Patil sold 1,200 shares of the stock in a transaction on Wednesday, June 10th. The shares were sold at an average price of $231.83, for a total value of $278,196.00. Following the completion of the transaction, the executive vice president directly owned 51,549 shares in the company, valued at approximately $11,950,604.67. This trade represents a 2.27% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 14,357 shares of company stock valued at $3,505,642. 4.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Jazz Pharmaceuticals

Several hedge funds have recently bought and sold shares of JAZZ. Triumph Capital Management lifted its stake in shares of Jazz Pharmaceuticals by 2.0% in the 2nd quarter. Triumph Capital Management now owns 2,597 shares of the specialty pharmaceutical company's stock valued at $626,000 after acquiring an additional 52 shares during the last quarter. Cardinal Capital Management grew its holdings in shares of Jazz Pharmaceuticals by 0.5% during the fourth quarter. Cardinal Capital Management now owns 14,538 shares of the specialty pharmaceutical company's stock valued at $2,471,000 after buying an additional 66 shares during the last quarter. Bessemer Group Inc. increased its holdings in Jazz Pharmaceuticals by 0.3% in the 1st quarter. Bessemer Group Inc. now owns 22,362 shares of the specialty pharmaceutical company's stock worth $4,228,000 after buying an additional 73 shares in the last quarter. UMB Bank n.a. grew its position in Jazz Pharmaceuticals by 12.6% in the 4th quarter. UMB Bank n.a. now owns 725 shares of the specialty pharmaceutical company's stock worth $123,000 after purchasing an additional 81 shares during the period. Finally, Pinnacle Associates Ltd. increased its position in shares of Jazz Pharmaceuticals by 0.7% during the 4th quarter. Pinnacle Associates Ltd. now owns 11,203 shares of the specialty pharmaceutical company's stock valued at $1,905,000 after purchasing an additional 83 shares during the last quarter. 89.14% of the stock is currently owned by institutional investors and hedge funds.

More Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: Needham & Company raised its price target for JAZZ from $292 to $310 and reaffirmed a “Buy” rating, implying approximately 19% upside from the referenced share price. The upgrade reflects confidence in Jazz’s growth outlook. Benzinga
• Positive Sentiment: The FDA approved two Ziihera (zanidatamab-hrii) regimens for first-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma. The broader label allows Ziihera with tislelizumab and chemotherapy for eligible patients regardless of PD-L1 status, potentially expanding the addressable market and establishing a new standard of care. FDA approval announcement
• Positive Sentiment: Coverage of the approval suggests Ziihera could become a blockbuster product, giving Jazz a potentially important commercial growth driver beyond its existing portfolio. Ziihera sales outlook
• Neutral Sentiment: Brokerages maintain an overall “Buy” recommendation for Jazz, reinforcing generally favorable Wall Street sentiment but providing limited incremental information beyond the Needham target increase. Brokerage recommendation
• Negative Sentiment: Jazz announced plans to issue $1.0 billion of exchangeable senior notes due 2032, with an option for up to an additional $150 million, while also repurchasing ordinary shares. The buybacks may support per-share value, but the financing adds debt-like obligations and could create future dilution if the notes are exchanged. Exchangeable notes and share repurchases

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company's research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz's product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source